- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00839202
Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay
January 31, 2017 updated by: Edward Gomperts, Children's Hospital Los Angeles
Pharmacokinetic (PK) Analysis of a Novel Immunoassay in Hemophilia A
A novel immuno-assay is being evaluated for the measurement of Factor VIII.
Current procedure measures a rate assay which is subject to much artefact.
The hypothesis is that the new assay will give a reading of absolute quantities of FVIII which will provide a more suitable indicator of FVIII content for clotting factor manufacturers, physicians and patients.
Study Overview
Detailed Description
Remnant samples collected in a clinical laboratory are assayed with the new procedure and compared with the standard functional activated partial thromboplastin time (APTT) assay.
A PK study in seven study subjects with hemophilia A is being carried out using five different commercially licensed factor VIII concentrates and the blood samples drawn for the PK analysis are being measured for FVIII with the novel assay and compared with the standard APTT assay.
The concentrates used in the PK studies are also being applied to the two assay systems to determine each product's specific activity.
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Vermont
-
Burlington, Vermont, United States, 05446
- Department of Biochemistry University of Vermont
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- adults with hemophilia A
- factor VIII less that 2%
- informed consent signed
- absence of an inhibitor
Exclusion Criteria:
- history of a high responding inhibitor anemia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FVIII immuno-assay
The study is not designed as a therapeutic evaluation, but an assessment of clotting factor VIII timed responses after the infusion of specified doses of licensed clotting factor VIII concentrates.
The purpose of the study is to measure the levels of infused licensed clotting factor VIII by standard assay techniques and comparing these standard assays with an experimental assay.
Measurements of possible co-factors that might impact the results were also carried out.
|
There is no intervention.
This is a study of the differences in assays.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The level of Factor VIII in pMols
Time Frame: 48 hours
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The possible role of VWF, factor concentrate type and non-inhibitory antibody presence or absence on the FVIII antigen levels
Time Frame: 48 hours
|
48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Edward D Gomperts, MD, Children's Hospital Los Angeles
- Principal Investigator: Kenneth G Mann, PhD, University of Vermont
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
September 1, 2008
Study Completion (Actual)
February 1, 2009
Study Registration Dates
First Submitted
February 6, 2009
First Submitted That Met QC Criteria
February 6, 2009
First Posted (Estimate)
February 9, 2009
Study Record Updates
Last Update Posted (Estimate)
February 1, 2017
Last Update Submitted That Met QC Criteria
January 31, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCI-06-0069-CR002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia A
-
Christoph KönigsRoche Pharma AG; Chugai Pharma Germany GmbHRecruitingSevere Hemophilia A | Severe Hemophilia A With Inhibitor | Severe Hemophilia A Without InhibitorGermany
-
GWT-TUD GmbHHannover Medical School; Hoffmann-La RocheCompleted
-
Kathelijn FischerRadboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingAdolescent | Child | Hemophilia A With Inhibitor | Adult | Hemophilia A Without Inhibitor | Hemophilia A, SevereNetherlands
-
Hoffmann-La RocheActive, not recruitingSevere Hemophilia A | Moderate Hemophilia ABrazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Morocco, Serbia
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
JW PharmaceuticalRecruitingHemophilia A With Inhibitor | Hemophilia A Without InhibitorKorea, Republic of
-
PfizerCompletedFactor VIII Deficiency, Congenital | Hemophilia A, Congenital | Factor 8 Deficiency, Congenital | Autosomal Hemophilia A | Classic Hemophilia
-
BioMarin PharmaceuticalRecruitingHemophilia A With Inhibitor | Hemophilia A With Anti Factor VIIIUnited States, United Kingdom, Taiwan, Israel, Korea, Republic of, South Africa, Brazil, Italy, Germany
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
BayerCompletedHemophilia A; Hemophilia BIsrael
Clinical Trials on FVIII immuno-assay
-
University of GhanaUniversity of Rostock; Shai-Osudoku District Hospital; Kumasi Technical University and other collaboratorsActive, not recruiting
-
Centre Hospitalier Universitaire, AmiensUnknownHIV Infections | ThyroidFrance
-
Universitas Katolik Widya Mandala SurabayaIndonesia's Ministry of Research and Technology (Ristekdikti/BRIN)CompletedImmune Defect | Lymphadenitis, TuberculousIndonesia
-
Universitätsmedizin MannheimCompletedImmuno-monitoringGermany
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Skane University HospitalCSL Behring; VersitiCompletedVon Willebrand DiseaseUnited States, Sweden
-
OctapharmaCompletedPrevent Bleeding in Major SurgeryUnited States, Turkey, Romania, India, Bulgaria, Italy, Oman, Poland, South Africa
-
BayerCompleted
-
Fondation LenvalRecruitingAttention Deficit With Hyperactivity DisorderFrance
-
University Hospital, MontpellierDepartment of the medical information of MontpellierCompletedCrohn's Disease | Ulcerative ColitisFrance